FCSC, BFAR, GNBT are active stocks in the news today.
Fibrocell Science, Inc. (OTCBB: FCSC) reached up 86.67% in morning trading to $.28 with 3M shares traded. Fibrocell Science, Inc. is an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well as its innovative cellular processing technology and manufacturing excellence. Fibrocell Science, Inc. (OTCBB: FCSC.OB - News) had rescheduled its fourth quarter 2011 business update investor conference call to today at 8:00 AM Eastern Time. The call will also be broadcast live over the Internet and can be accessed on the Investors section of the Company’s website at www.fibrocellscience.com.
Biopharm Asia, Inc. (PINK: BFAR) reached up 46.67% in morning trading to $.088 with 500K shares traded. Biopharm Asia, Inc. is engaged in the retail sale of medical services and products in China, complemented by vertically integrated supporting functions that include the cultivation of Chinese herbal medicines, pharmaceutical production and wholesale medicine distribution. Biopharm Asia, Inc. (Pinksheets: BFAR.PK - News) announced a status update regarding restated financial results of 2008, 2009 and 2010. As the restatement process is not yet complete, the Company delayed in filing its 10-K, which was due on March 31, 2012, for the fiscal year ending on December 31, 2011. The Board of Directors made the restatement process a critical priority; management retained additional accounting staff to work with the Company's outside consultant and auditor to complete the requisite bookkeeping and associated statement preparation. However, the Company has not set a timetable for completion of this evaluation process and there can be no assurances that this review will result in any action.
Generex Biotechnology Corporation (OTCBB: GNBT) reached up 13.93% in morning trading to $.139 with 2M shares traded. Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that the American Association for Cancer Research (AACR) chose to spotlight a presentation on data from the ongoing clinical trial of AE37, an immunotherapeutic vaccine to prevent relapse in patients who have had breast cancer being developed by Antigen Express, in a press conference.
For a detailed quote on any of the following companies, or to read the full news articles visit PennyTrader.com
PennyTrader.com is a financial and investor relations website committed to covering the microcap market space including Pink Sheets and OTC Bulletin Board and sub-$5 big board stocks. We strive to provide you with the best stocks alerts in the market! We focus on OTCBB, OTC, penny stocks, sub-$5 big board stocks, and timely stocks picks and alerts. Our goal is to inform you of the HOTTEST stocks in the market before they move. Our staff has years experience in the stock market, and we are confident that you’ll be impressed with the results of our stock picks! If you wish to feature your organization on our website then you can contact us at email@example.com.
Disclosure: PennyTrader.com is not currently being compensated for any stocks covered in this midday report.
PennyTrader.com is not a registered investment advisers or broker/dealer. PennyTrader.com makes no recommendation that the purchase of securities of companies profiled in this press release is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the micro cap companies covered and the potential lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. For our full disclaimer go to CLICK HERE